FDA chief appointment delays major drug approvals by Q3 2026

If a pro-industry FDA commissioner is confirmed, the agency will fast-track at least 5 high-profile drug applications by September 2026, risking safety oversights. Industry pressure will outweigh public health concerns in key decisions.

Implied probability (Yes)

70%